Pfizer (PFE) is in a clear downtrend, with both the 9- and 21-day EMAs sloping downward and the stock trading below them—classic bearish vibes. 📉 The RSI hovering around 30 suggests it’s nearing oversold territory, but no reversal signs yet. Volume spiked on down days, confirming selling pressure. News hints at undervaluation and dividend appeal, but with Trump’s pharma tariffs looming, caution’s key. For now, it’s a hold unless buyers step in or RSI rebounds convincingly. 🚦 #WaitForConfirmation

"Pfizer’s stock is like a phoenix rising from the COVID vaccine drama—news hints at a turnaround, but the charts are still shaking off the shivers. 📉 RSI’s at a ‘meh’ 47, and the 9-period WMA is flirting with a bullish crossover. Volume’s decent, but not screaming ‘all-in.’ With Trump’s drug pricing order less scary than feared and dividend chatter swirling, I’d say BUY on dips—this could be the calm before the rebound. 💊 #VaccineForYourPortfolio"

"Pharma stocks are sweating bullets after Trump’s drug pricing order, but PFE’s 7.6% yield is looking juicy like a discount latte. 📉 RSI’s chilling in the 40s (not oversold, just napping), and volume spiked like a caffeine rush on the 14th. Chart’s messy—like a barista during rush hour—but the 9-day EMA is flirting with a bullish crossover. News says 'not as bad as feared,' and value hunters are circling. BUY the dip, but keep an eye on political drama. #BargainHunting ☕"

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc. PFE: 25.16 USD